EA202193344A1 - SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIATIC ARTHRITIS WITH IL-23 SPECIFIC ANTIBODY - Google Patents

SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIATIC ARTHRITIS WITH IL-23 SPECIFIC ANTIBODY

Info

Publication number
EA202193344A1
EA202193344A1 EA202193344A EA202193344A EA202193344A1 EA 202193344 A1 EA202193344 A1 EA 202193344A1 EA 202193344 A EA202193344 A EA 202193344A EA 202193344 A EA202193344 A EA 202193344A EA 202193344 A1 EA202193344 A1 EA 202193344A1
Authority
EA
Eurasian Patent Office
Prior art keywords
specific antibody
psoriatic arthritis
safe
treatment
effective method
Prior art date
Application number
EA202193344A
Other languages
Russian (ru)
Inventor
Элизабет Хсиа
Алекса Коллмейер
Се Сюй
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Priority claimed from PCT/IB2020/055278 external-priority patent/WO2020245766A1/en
Publication of EA202193344A1 publication Critical patent/EA202193344A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Способ лечения псориатического артрита у пациента путем введения специфического к ИЛ-23 антитела, например гуселькумаба, в клинически доказанном безопасном и клинически доказанном эффективном количестве, и указанный пациент достигает значительного улучшения по клиническим конечным показателям, таким как ACR20/50/70, IGA, HAQ-DI, СРБ, PCS/MCS SF-36, MDA, VLDA, энтезит, дактилит и LEI/дактилит, измеренные через 16 и 24 недели после начального лечения.A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., Guselcumab, in a clinically proven safe and clinically proven effective amount, and said patient achieves significant improvement in clinical endpoints such as ACR20/50/70, IGA, HAQ -DI, CRP, PCS/MCS SF-36, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis measured at 16 and 24 weeks after initial treatment.

EA202193344A 2020-03-23 2020-06-04 SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIATIC ARTHRITIS WITH IL-23 SPECIFIC ANTIBODY EA202193344A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062993259P 2020-03-23 2020-03-23
PCT/IB2020/055278 WO2020245766A1 (en) 2019-06-04 2020-06-04 Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody

Publications (1)

Publication Number Publication Date
EA202193344A1 true EA202193344A1 (en) 2022-03-14

Family

ID=81077510

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193344A EA202193344A1 (en) 2020-03-23 2020-06-04 SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIATIC ARTHRITIS WITH IL-23 SPECIFIC ANTIBODY

Country Status (1)

Country Link
EA (1) EA202193344A1 (en)

Similar Documents

Publication Publication Date Title
MX2021014953A (en) Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody.
EA201892190A1 (en) TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
MX2020004716A (en) Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody.
MX2021001762A (en) Method and composition for stimulating immune response.
AR091462A1 (en) ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE
JOP20200156A1 (en) Esketamine for the treatment of depression
MX2019005661A (en) Method of treating psoriasis with anti-il-23 specific antibody.
JP2018505882A5 (en)
CL2021002533A1 (en) Compositions and methods for treating diseases or disorders associated with kras
MX2019003703A (en) Safe and effective method of treating psoriasis with anti-il23 specific antibody.
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
FI13575Y1 (en) IL12/IL23 antibody to be used in a safe and efficient method for treating ulcerative colitis
JP2020500152A5 (en)
MX2020009265A (en) Methods of treating crohn's disease with anti-il23 specific antibody.
EA202193344A1 (en) SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIATIC ARTHRITIS WITH IL-23 SPECIFIC ANTIBODY
BR112023018400A2 (en) METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TNF THERAPY WITH SPECIFIC ANTI-IL23 ANTIBODY
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2022013923A (en) Methods of treating crohn's disease with anti-il23 specific antibody.
RU2017100658A (en) THERAPEUTIC AGAINST Helicobacter
EA202191947A1 (en) METHODS FOR TREATING PAIN WITH THIAZOLINE ANTIHYPERALGESIC DRUG
BR112023018353A2 (en) SAFE AND EFFECTIVE METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS WITH SPECIFIC ANTI-IL23 ANTIBODY
MX2021005905A (en) Safe and effective method of treating psoriasis with anti-il-23 specific antibody.
CL2023001201A1 (en) Regimens for treatment of hair loss disorders with deuterated jak inhibitors
AR126578A1 (en) ANTI-CCR8 ANTIBODIES
EA202191423A1 (en) SAFE AND EFFECTIVE METHOD FOR TREATMENT OF PSORIASIS WITH ANTIBODY SPECIFIC TO IL-23